Tags: Drug.

Laniquidar (INN) is a P-glycoprotein inhibitor undergoing clinical studies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Laniquidar.png
ATC prefix
none
CAS number
197509-46-9
FDA UNII code
K3FRN4DDOY
IUPAC name
methyl 11-(1-2-[4-(quinolin-2-ylmethoxy)phenyl]ethylpiperidin-4-ylidene)-611-dihydro-5H-imidazo[21-b][3]benzazepine-3-carboxylate
PubChem
6450806

Loading...

This page contains content from the copyrighted Wikipedia article "Laniquidar"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.